Developer docs
API playgroundTry for free, no card

Search company profiles

ScreenIn3D

Full company profile

uuid00038hb

Namestring
ScreenIn3D
Legal namestring
ScreenIn3D Limited
Websiteurl
screenin3d.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

ScreenIn3D Limited is a Glasgow-based precision medicine company that has developed UpScale3D®, a patented lab-on-a-chip screening platform combining microfluidic technology with 3D cell culture for drug discovery applications. The platform supports spheroids, organoids, and 3D co-cultures built from patient-derived tissue, and is differentiated by shear-stress-free perfusion that requires no tubing, syringe pumps, or rocking plates, miniaturization that yields at least 20 times more data than standard methods using only a few thousand cells, and a microplate form factor designed to be plug-and-play with standard imaging equipment and robotic dispensers. Founded in 2018 as a spin-off of the University of Strathclyde, the company serves pharmaceutical and biotech customers developing small molecules, biologics, and cell and gene therapies across oncology (glioblastoma, breast, endometrial, colorectal, ovarian, prostate, and lung cancers), immuno-oncology (including CAR-T), and women's health (endometriosis and fibroid disease).

The company operates a B2B professional-services business model, monetizing through quote-based custom contracts. Its revenue streams include 3D in vitro drug efficacy screening, custom assay design, 3D co-culture development using patient-derived tissue, and single and combination drug testing (including chemo- and radio-therapy regimens). Distribution is via direct enterprise sales supplemented by CRO partnerships, most notably a strategic co-development alliance with RoukenBio in immuno-oncology, and a partnership with Inaphaea BioLabs that gives ScreenIn3D access to over 470 patient-derived cells across 66 cancer types. Pricing is not publicly disclosed and there is no self-serve or e-commerce channel.

ScreenIn3D is a small, privately held company of approximately 10 employees, led by co-founders Prof. Michele Zagnoni (CEO) and Alex Sim (Chairman), with a senior engineer, senior scientist, scientist, and additional team members, plus investor director Fiona Nicolson. It is backed by the University of Strathclyde alongside Scottish Enterprise, TRICAPITAL (lead investor in a June 2025 round), Gabriel Investments, and Nidobirds Ventures, with a total disclosed funding round of approximately $1.02M. AstraZeneca (through Steve Rees, VP Discovery Biology) is the only named enterprise validation customer, citing direct applicability of the technology in target discovery, combination screening, and treatment regime determination.

Short descriptiontext

ScreenIn3D is a Glasgow-based precision medicine company offering the patented UpScale3D® lab-on-a-chip platform and 3D cell-culture screening services to pharmaceutical and biotech clients developing drugs across oncology, immuno-oncology, and women's health.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGlasgow, United Kingdom
HQ citystring
Glasgow
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug screening services, 3D cell culture, microfluidic screening platform, lab-on-a-chip technology, preclinical drug discovery
Industry3 codes
PRIMARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHLAFAMAL
Clinical Research & Trial Central Laboratories
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Medical Laboratories621511
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Testing Laboratories8734
Product category
Drug Discovery Services
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
13D In Vitro Drug Efficacy Screening Services
TypeProfessional Services
Description

Provides contracted screening services using the UpScale3D platform. Guides clients on disease model generation, defines assay conditions, and delivers results. Revenue generated through service contracts for drug efficacy testing on 3D translational models.

screenin3d.com
2Custom Assay Development
TypeProfessional Services
Description

Collaborative assay design services tailored to client study goals. Includes sequential cell seeding for time-dependent modeling and scalable drug testing across 3D models.

screenin3d.com
33D Co-Culture Development
TypeProfessional Services
Description

Generation of tumoroids and complex 3D in vitro models using patient-derived tissue for evaluating compound effects across biological systems.

screenin3d.com
4Drug Combination Screening
TypeProfessional Services
Description

Single and combination drug testing services including chemo- and radio-therapy regimens, mimicking clinical dosing protocols in vitro.

screenin3d.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1UpScale3D
Description

Patented lab-on-a-chip screening platform technology with associated image analysis software for cost-effective, high quality, large-throughput and data-rich assays.

screenin3d.com
Core offering1 text field

ScreenIn3D commercializes the patented UpScale3D® lab-on-a-chip platform and offers contract screening services that test drug efficacy on miniaturized 3D human disease models (spheroids, tumoroids, organoids). The company combines microfluidic technology with patient-derived tissue to deliver high-throughput drug efficacy, custom assay development, 3D co-culture, and combination drug screening services to pharmaceutical and biotechnology customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 20X more data for the same starting material
+2 more records
Product overview1 text field

ScreenIn3D offers the UpScale3D® patented lab-on-a-chip platform as its core product, which provides a microplate-based screening system with image analysis software for large-throughput 3D drug screening. This platform is complemented by a suite of service offerings including 3D in vitro drug efficacy testing, development of 3D co-cultures, custom assay design, and single/combination drug testing services. The platform supports multiple therapy modalities including small molecules, biologics, and cell and gene therapies, with applications spanning oncology, immuno-oncology, and women's health disease models.

Product and service6 records
1UpScale3D®
CategoryDrug discovery platform / lab-on-a-chip technology
Description

Patented lab-on-a-chip screening platform with associated image analysis software that enables cost-effective, high-quality, large-throughput, data-rich 3D drug screening assays in a microplate format compatible with existing imaging equipment and robotic dispensers. Used by pharmaceutical and biotech customers to test drug efficacy on 3D disease models.

23D In Vitro Drug Efficacy Screening
CategoryDrug discovery services
Description

Contracted screening service that miniaturizes and upscales generation of 3D translational in vitro models with drug efficacy testing and assay-specific readouts. Sold to pharmaceutical and biotech customers for preclinical drug discovery.

33D Co-Culture Development
CategoryDrug discovery services
Description

Generation of tumoroids and complex 3D in vitro models using patient-derived tissue that simulate cell-cell interactions and quantify cell-drug responses at scale. Sold to pharma and biotech customers developing oncology and immuno-oncology therapies.

4Custom Assay Design
CategoryDrug discovery services
Description

Tailored assay development collaboration that builds assays reflecting real disease complexity, with sequential cell seeding and scalable drug testing across 3D models. Sold to pharma and biotech clients requiring bespoke preclinical assays.

5Single & Combination Drug Screening
CategoryDrug discovery services
Description

Evaluation of compounds alone or in combination, including multi-format combination screening with chemo- and radio-therapy regimens that mimic clinical dosing protocols in vitro. Sold to pharma and biotech clients for preclinical candidate selection.

6CAR-T 3D Assay Service
CategoryDrug discovery services
Description

High-throughput miniaturized CAR-T cell therapy efficacy assays that test cytotoxicity of T-cell therapies on spheroid co-cultures and organoids. Sold to immuno-oncology and cell therapy developers needing predictive preclinical CAR-T models.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership between ScreenIn3D and RoukenBio delivering next-generation 3D in vitro platforms for immune-oncology. Combines RoukenBio's immunology expertise and bespoke assay development with ScreenIn3D's cutting-edge 3D miniaturized microfluidic technology. Enables advanced physiologically relevant assays that accelerate and de-risk drug discovery efforts for CAR-T and immunotherapy testing.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership providing patient-derived cells (PDCs) and cell-based assays focused on oncology and women's health. Inaphaea offers over 470 PDCs across 66 types of cancer from its biobank. Partnership supports translational drug development by providing data-driven insights into cancer cell activity using ScreenIn3D's screening platform.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Provides 3D cell-based predictive drug response assays for oncology drug development, sharing ScreenIn3D's emphasis on human-relevant 3D ex vivo prediction in cancer screening.

TypeDirect peer
Description

Develops multi-organ-chip and microphysiological platforms for preclinical drug testing, competing in microfluidic organ-on-chip drug screening for pharmaceutical customers.

3CN Bio Innovations
TypeDirect peer
Description

Provides organ-on-chip and microphysiological systems for preclinical drug discovery, directly overlapping with ScreenIn3D's UpScale3D microfluidic 3D culture platform in target customers and use cases.

TypeDirect peer
Description

Develops OrganoPlate microfluidic 3D tissue models for high-throughput drug screening, offering an overlapping organ-on-chip service and product model for pharma preclinical testing.

TypeDirect peer
Description

Commercializes the Emulate organ-chip platform for human-relevant disease modeling and drug discovery, competing for the same pharma preclinical 3D screening budget as ScreenIn3D.

TypeDirect peer
Description

Provides 3D spheroid and organoid-based assay services and platforms for drug discovery, directly comparable to ScreenIn3D's 3D in vitro disease model screening offering.

TypeBroad incumbent
Description

Large preclinical CRO offering in vivo and in vitro oncology services including 3D model screening; an incumbent alternative for pharma customers evaluating specialized 3D providers like ScreenIn3D.

TypeEmerging player
Description

Builds microfluidic organ-on-chip devices for drug delivery and screening research, with overlapping lab-on-a-chip technology and pharma customer base.

TypeBroad incumbent
Description

Supplies high-throughput screening instruments and software for drug discovery, representing a broad incumbent whose microplate readers and automation ecosystem compete for the same screening workflow budgets.

TypeOthers
Description

Strategic immunology CRO partner of ScreenIn3D; comparable as a UK-based specialist immuno-oncology assay CRO addressing the same pharma customer segment through complementary capabilities.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ScreenIn3D

Drug Discovery Servicesscreenin3d.com

ScreenIn3D is a Glasgow-based precision medicine company offering the patented UpScale3D® lab-on-a-chip platform and 3D cell-culture screening services to pharmaceutical and biotech clients developing drugs across oncology, immuno-oncology, and women's health.

What ScreenIn3D does

ScreenIn3D Limited is a Glasgow-based precision medicine company that has developed UpScale3D®, a patented lab-on-a-chip screening platform combining microfluidic technology with 3D cell culture for drug discovery applications. The platform supports spheroids, organoids, and 3D co-cultures built from patient-derived tissue, and is differentiated by shear-stress-free perfusion that requires no tubing, syringe pumps, or rocking plates, miniaturization that yields at least 20 times more data than standard methods using only a few thousand cells, and a microplate form factor designed to be plug-and-play with standard imaging equipment and robotic dispensers. Founded in 2018 as a spin-off of the University of Strathclyde, the company serves pharmaceutical and biotech customers developing small molecules, biologics, and cell and gene therapies across oncology (glioblastoma, breast, endometrial, colorectal, ovarian, prostate, and lung cancers), immuno-oncology (including CAR-T), and women's health (endometriosis and fibroid disease).

The company operates a B2B professional-services business model, monetizing through quote-based custom contracts. Its revenue streams include 3D in vitro drug efficacy screening, custom assay design, 3D co-culture development using patient-derived tissue, and single and combination drug testing (including chemo- and radio-therapy regimens). Distribution is via direct enterprise sales supplemented by CRO partnerships, most notably a strategic co-development alliance with RoukenBio in immuno-oncology, and a partnership with Inaphaea BioLabs that gives ScreenIn3D access to over 470 patient-derived cells across 66 cancer types. Pricing is not publicly disclosed and there is no self-serve or e-commerce channel.

ScreenIn3D is a small, privately held company of approximately 10 employees, led by co-founders Prof. Michele Zagnoni (CEO) and Alex Sim (Chairman), with a senior engineer, senior scientist, scientist, and additional team members, plus investor director Fiona Nicolson. It is backed by the University of Strathclyde alongside Scottish Enterprise, TRICAPITAL (lead investor in a June 2025 round), Gabriel Investments, and Nidobirds Ventures, with a total disclosed funding round of approximately $1.02M. AstraZeneca (through Steve Rees, VP Discovery Biology) is the only named enterprise validation customer, citing direct applicability of the technology in target discovery, combination screening, and treatment regime determination.

ScreenIn3D firmographics

Firmographics
Name
ScreenIn3D
Legal name
ScreenIn3D Limited
Website
https://screenin3d.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
ScreenIn3D is a Glasgow-based precision medicine company offering the patented UpScale3D® lab-on-a-chip platform and 3D cell-culture screening services to pharmaceutical and biotech clients developing drugs across oncology, immuno-oncology, and women's health.
Ownership category
akta.pro rank

ScreenIn3D industry classification

Industry
Product category
Drug Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical Laboratories (621511)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHLAFAMAL
Clinical Research & Trial Central Laboratories

Keywords

  • Drug screening services
  • 3D cell culture
  • Microfluidic screening platform
  • Lab-on-a-chip technology
  • Preclinical drug discovery

Where ScreenIn3D is headquartered

Location

Headquarters

HQ city
Glasgow
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

ScreenIn3D business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. 3D In Vitro Drug Efficacy Screening Services: Provides contracted screening services using the UpScale3D platform. Guides clients on disease model generation, defines assay conditions, and delivers results. Revenue generated through service contracts for drug efficacy testing on 3D translational models.
  2. Custom Assay Development: Collaborative assay design services tailored to client study goals. Includes sequential cell seeding for time-dependent modeling and scalable drug testing across 3D models.
  3. 3D Co-Culture Development: Generation of tumoroids and complex 3D in vitro models using patient-derived tissue for evaluating compound effects across biological systems.
  4. Drug Combination Screening: Single and combination drug testing services including chemo- and radio-therapy regimens, mimicking clinical dosing protocols in vitro.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

ScreenIn3D product offering

Product offering

Core offering

ScreenIn3D commercializes the patented UpScale3D® lab-on-a-chip platform and offers contract screening services that test drug efficacy on miniaturized 3D human disease models (spheroids, tumoroids, organoids). The company combines microfluidic technology with patient-derived tissue to deliver high-throughput drug efficacy, custom assay development, 3D co-culture, and combination drug screening services to pharmaceutical and biotechnology customers.

Product overview

ScreenIn3D offers the UpScale3D® patented lab-on-a-chip platform as its core product, which provides a microplate-based screening system with image analysis software for large-throughput 3D drug screening. This platform is complemented by a suite of service offerings including 3D in vitro drug efficacy testing, development of 3D co-cultures, custom assay design, and single/combination drug testing services. The platform supports multiple therapy modalities including small molecules, biologics, and cell and gene therapies, with applications spanning oncology, immuno-oncology, and women's health disease models.

Differentiator

Problem solved

Functional benefit

Brands

  • UpScale3D: Patented lab-on-a-chip screening platform technology with associated image analysis software for cost-effective, high quality, large-throughput and data-rich assays.

Products and services

  • UpScale3D® Patented lab-on-a-chip screening platform with associated image analysis software that enables cost-effective, high-quality, large-throughput, data-rich 3D drug screening assays in a microplate format compatible with existing imaging equipment and robotic dispensers. Used by pharmaceutical and biotech customers to test drug efficacy on 3D disease models.
  • 3D In Vitro Drug Efficacy Screening Contracted screening service that miniaturizes and upscales generation of 3D translational in vitro models with drug efficacy testing and assay-specific readouts. Sold to pharmaceutical and biotech customers for preclinical drug discovery.
  • 3D Co-Culture Development Generation of tumoroids and complex 3D in vitro models using patient-derived tissue that simulate cell-cell interactions and quantify cell-drug responses at scale. Sold to pharma and biotech customers developing oncology and immuno-oncology therapies.
  • Custom Assay Design Tailored assay development collaboration that builds assays reflecting real disease complexity, with sequential cell seeding and scalable drug testing across 3D models. Sold to pharma and biotech clients requiring bespoke preclinical assays.
  • Single & Combination Drug Screening Evaluation of compounds alone or in combination, including multi-format combination screening with chemo- and radio-therapy regimens that mimic clinical dosing protocols in vitro. Sold to pharma and biotech clients for preclinical candidate selection.
  • CAR-T 3D Assay Service High-throughput miniaturized CAR-T cell therapy efficacy assays that test cytotoxicity of T-cell therapies on spheroid co-cultures and organoids. Sold to immuno-oncology and cell therapy developers needing predictive preclinical CAR-T models.

Quantifiable outcome

  • 20X more data for the same starting material
  • +2 more outcomes

Companies that use ScreenIn3D

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

ScreenIn3D technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

ScreenIn3D partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • RoukenBiocoreStrategic or Co-development PartnerStrategic partnership between ScreenIn3D and RoukenBio delivering next-generation 3D in vitro platforms for immune-oncology. Combines RoukenBio's immunology expertise and bespoke assay development with ScreenIn3D's cutting-edge 3D miniaturized microfluidic technology. Enables advanced physiologically relevant assays that accelerate and de-risk drug discovery efforts for CAR-T and immunotherapy testing.
  • Inaphaea BioLabscoreStrategic or Co-development PartnerStrategic partnership providing patient-derived cells (PDCs) and cell-based assays focused on oncology and women's health. Inaphaea offers over 470 PDCs across 66 types of cancer from its biobank. Partnership supports translational drug development by providing data-driven insights into cancer cell activity using ScreenIn3D's screening platform.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

ScreenIn3D competitors and assessment

Company assessment

Emerging players

  • Kiyatec: Provides 3D cell-based predictive drug response assays for oncology drug development, sharing ScreenIn3D's emphasis on human-relevant 3D ex vivo prediction in cancer screening.
  • SynVivo: Builds microfluidic organ-on-chip devices for drug delivery and screening research, with overlapping lab-on-a-chip technology and pharma customer base.

Direct peers

  • TissUse: Develops multi-organ-chip and microphysiological platforms for preclinical drug testing, competing in microfluidic organ-on-chip drug screening for pharmaceutical customers.
  • CN Bio Innovations: Provides organ-on-chip and microphysiological systems for preclinical drug discovery, directly overlapping with ScreenIn3D's UpScale3D microfluidic 3D culture platform in target customers and use cases.
  • MIMETAS: Develops OrganoPlate microfluidic 3D tissue models for high-throughput drug screening, offering an overlapping organ-on-chip service and product model for pharma preclinical testing.
  • Emulate Inc. Commercializes the Emulate organ-chip platform for human-relevant disease modeling and drug discovery, competing for the same pharma preclinical 3D screening budget as ScreenIn3D.
  • InSphero: Provides 3D spheroid and organoid-based assay services and platforms for drug discovery, directly comparable to ScreenIn3D's 3D in vitro disease model screening offering.

Broad incumbents

  • Crown Bioscience (JSR Life Sciences): Large preclinical CRO offering in vivo and in vitro oncology services including 3D model screening; an incumbent alternative for pharma customers evaluating specialized 3D providers like ScreenIn3D.
  • Molecular Devices (Danaher): Supplies high-throughput screening instruments and software for drug discovery, representing a broad incumbent whose microplate readers and automation ecosystem compete for the same screening workflow budgets.

Others

  • RoukenBio: Strategic immunology CRO partner of ScreenIn3D; comparable as a UK-based specialist immuno-oncology assay CRO addressing the same pharma customer segment through complementary capabilities.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

ScreenIn3D social profiles

Digital presence

ScreenIn3D financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ScreenIn3D leadership team

Management profile

Number of profiles

Profiles9 records

ScreenIn3D funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ScreenIn3D M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ScreenIn3D

What does ScreenIn3D do?

ScreenIn3D commercializes the patented UpScale3D® lab-on-a-chip platform and offers contract screening services that test drug efficacy on miniaturized 3D human disease models (spheroids, tumoroids, organoids). The company combines microfluidic technology with patient-derived tissue to deliver high-throughput drug efficacy, custom assay development, 3D co-culture, and combination drug screening services to pharmaceutical and biotechnology customers.

Is ScreenIn3D a public or private company?

ScreenIn3D is a private company. It is classified as venture growth investor backed and is currently operating.

When was ScreenIn3D founded?

ScreenIn3D was founded in 2018. It employs 11 to 50 people.

Where is ScreenIn3D based?

ScreenIn3D is headquartered in Glasgow, United Kingdom, in the Europe region.

How does ScreenIn3D make money?

Four revenue lines are on record. 3D In Vitro Drug Efficacy Screening Services are the primary driver. The others are custom Assay Development, 3D Co-Culture Development and drug Combination Screening.

Who are ScreenIn3D's main competitors?

Emerging players on record are Kiyatec and SynVivo. Direct peers are TissUse, CN Bio Innovations, MIMETAS, Emulate Inc. and InSphero. Broad incumbents are Crown Bioscience (JSR Life Sciences) and Molecular Devices (Danaher). RoukenBio is listed as an others.

Does ScreenIn3D have an API?

No public API is recorded for ScreenIn3D.

What industry is ScreenIn3D in?

ScreenIn3D's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAAAIAA, High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening), with a secondary code of HLAGADAH, Cell-Based & Potency Assays (Bioassays). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals